OLTB wrote:I am contemplating my next purchase from accumulated dividends and it seems that in spite of my previous top-up mentioned above, GNK is once again in pole position! Now, I am thinking once Carillioned twice shy, and may ignore this and go for the second or third in the queue (Vodafone / Glaxo respectively). Waiting until GNK's trading update at the end of November seems prudent. Vodafone and Glaxo have their issues (Vodafone's P/E seems to make it expensive at nearly 30 and Glaxo has a fairly static dividend policy will either not grow in the short term or even fall if Emma Walmsley isn't happy where the cover figure is - not very HYP). They are, however, larger cap than GNK which gives me a little more comfort! Not very SI is it
Cheers, OLTB.
There is no rule that says the top-up ranking has to be obeyed. It's not unusual for the same share to be top of the rankings when you are next ready to act, and a falling share price can have this effect. This is one reason why I put a limit on share of cost, to avoid sinking too much cash in one share.
If you know that results are coming soon, that can be an argument for either delay or acceleration, depending on your views of how the results might go. Picking the second or even the third choice is not a hanging offence. SI does not require that you stick your head in the sand.
TJH